606-P: Addressing Diabetes Distress in Clinical Practice—Provider Feedback and Resource Gaps following Screening Implementation

Le résumé fourni par la source

Introduction and Objective: While diabetes-related distress is common, healthcare systems may lack resources for adequately addressing this aspect of diabetes care. As part of a quality improvement initiative, we surveyed providers after implementation of annual diabetes distress (DD) screening for persons with Type 1 diabetes (PwT1D) in an academic center with the goal of better understanding how to best address DD in clinical practice. Methods: PwT1D were assigned the Type 1 Diabetes Distress Assessment System (T1DDAS) core scale prior to their adult endocrinology visits with results visible to providers in the electronic medical record during the clinical encounter. Providers were surveyed 1-year after screening implementation. Results: Between December 2023-2024, 2,081 T1DDAS questionnaires were completed by 1,852 unique patients out of 2,452 eligible patients (75.5%). The average score was 1.84±0.88 with 22.9% (n=477) reporting moderate (2.0-2.9) and 12.9% (n=268) reporting high (>3.0) distress. Sixteen of 42 providers responded (38%) to the post-implementation survey. While 15 (94%) agreed that DD is an important to address, only 11 (69%) felt confident in their ability to identify DD, and 3 (19%) were satisfied with the resources currently available to address DD. The most common barriers were limited clinic time (56%), inadequate resources (56%), and insufficient training (31%). Providers identified social work referrals, an embedded psychologist, and handouts with local mental health resources as the most helpful supports for patients with DD. Conclusion: Over one-third of PwT1D in our clinic reported moderate to high diabetes distress (DD), emphasizing the need for strategies to address elevated DD scores. Providers recognize the importance of addressing DD but express dissatisfaction with available resources. These findings will guide future Plan-Do-Check-Act cycles to improve support for PwT1D experiencing DD. Disclosure J.J. Iyengar: None. H. Centola: None. D. Broome: Research Support; Fractyl Health, Inc., Sanofi, T1D Exchange, Rhythm Pharmaceuticals, Inc, Novo Nordisk. K.R. Mizokami-Stout: None. L. Ang: None. J. Lee: None. J. Wyckoff: None. B. Mezuk: None. S. Soleimanpour: Research Support; Ono Pharmaceutical Co., Ltd. J.M. Lee: Advisory Panel; GoodRx. Funding Michigan Nutrition Obesity Research Center (P30DK089503), Michigan Diabetes Research Center (P30DK020572), Michigan Center for Diabetes Translational Research (P30DK092926), the Elizabeth Weiser Caswell Diabetes Institute, and the Breakthrough T1D Center of Excellence at the University of Michigan.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.